Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
Status:
Not yet recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of attention deficit
hyperactivity disorder (ADHD). It is unknown, however, if stimulants would be of benefit for
memory and thinking problems due to epilepsy. In this study, participants will be assigned
randomly (i.e., by flip of a coin), to a group that takes MPH and a group that takes a
placebo (sugar pill). Participants will not know the group to which they have been assigned.
Tests of attention and memory will be completed before taking the study pills, at Week 4, and
at Week 8. All participants will then have the option of taking MPH for the next two months,
and attention and memory will be tested again at Week 16. The study will determine whether
methylphenidate is helpful for the treatment of attention and memory problems in adults with
epilepsy, and whether the medication is safe and beneficial when taken over an extended time
period.
Phase:
Phase 4
Details
Lead Sponsor:
VA New York Harbor Healthcare System
Collaborators:
Miami VA Healthcare System Portland VA Medical Center